Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

被引:5
|
作者
Gotfredsen, Ditte Resendal [1 ]
Vinther, Siri [1 ]
Petersen, Tonny Studsgaard [1 ,2 ]
Cortes, Rikke [1 ]
Jensen, Thomas Bo [1 ,2 ]
Jimenez-Solem, Espen [1 ,2 ]
Christensen, Mikkel Bring [1 ,2 ,3 ]
机构
[1] Bispebjerg & Frederiksberg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
关键词
OLDER-ADULTS; SEVERE HYPOGLYCEMIA; POTENTIAL OVERTREATMENT; MELLITUS; TRENDS; PEOPLE; ASSOCIATION; PREVALENCE; GUIDELINES; EVENTS;
D O I
10.1038/s41598-020-60818-5
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012-2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals' records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA(1c) in the range recommended for frail, comorbid, older patients with type 2 diabetes (58-75 mmol/mol (7.5-9%)). Half of the patients (n = 2,575) had an HbA1c <48 mmol/mol (<6.5%), and a majority of these (36% of all patients) did not meet the diagnostic criteria for T2D. Of patients treated with one or more glucose-lowering medications (n = 1,758), 20% had HbA(1c)-values <42 mmol/mol (<6%), and 1% had critically low Hba(1c) values <30 mmol/mol (<4.9%), In conclusion, among these hospitalized T2D patients, few had an HbA(1c) within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA(1c)-values suggesting overtreatment.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Exploring Metabolomic Patterns in Type 2 Diabetes Mellitus and Response to Glucose-Lowering Medications-Review
    Shahisavandi, Mina
    Wang, Kan
    Ghanbari, Mohsen
    Ahmadizar, Fariba
    GENES, 2023, 14 (07)
  • [32] Personalized glucose-lowering effect of chiglitazar in type 2 diabetes
    Huang, Qi
    Zou, Xiantong
    Chen, Yingli
    Gao, Leili
    Cai, Xiaoling
    Zhou, Lingli
    Gao, Fei
    Zhou, Jian
    Jia, Weiping
    Ji, Linong
    ISCIENCE, 2023, 26 (11)
  • [33] Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
    Kabadi, Udaya M.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (01) : 140 - 140
  • [34] Trial Compares Glucose-Lowering Drugs for Type 2 Diabetes
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (16): : 1581 - 1581
  • [35] Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
    Ahren, Bo
    DIABETOLOGIA, 2015, 58 (08) : 1740 - 1744
  • [36] Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?
    Bo Ahrén
    Diabetologia, 2015, 58 : 1740 - 1744
  • [37] The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes
    Pauline A. J. Vissers
    Chris R. Cardwell
    Lonneke V. van de Poll-Franse
    Ian S. Young
    Frans Pouwer
    Liam J. Murray
    Breast Cancer Research and Treatment, 2015, 150 : 427 - 437
  • [38] The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes
    Vissers, Pauline A. J.
    Cardwell, Chris R.
    van de Poll-Franse, Lonneke V.
    Young, Ian S.
    Pouwer, Frans
    Murray, Liam J.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (02) : 427 - 437
  • [39] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update
    Tomlinson, Brian
    Chan, Paul
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (04) : 175 - 179
  • [40] Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice
    Spoelstra, JA
    Stolk, RP
    Klungel, OH
    Erkens, JA
    Rutten, GEHM
    Leufkens, HGM
    Grobbee, DE
    DIABETIC MEDICINE, 2004, 21 (08) : 896 - 900